Letter to the editor regarding 'A prospective, controlled study of the botanical compound mixture LCS101 for chemotherapy-induced hematological complications in breast cancer' by Yaal-Hahoshen et al. (The Oncologist 2011;16:1197-1202)

摘要

Based on the results of a prospective, randomized, placebo-controlled study of Yaal-Hahoshen et al, [1] the authors concluded that the botanical mixture LCS101 prevented hematological complications in breast cancer patients undergoing anthracycline- and taxane-based chemotherapy. They also concluded that the addition of LCS101 to conventional chemotherapy regimens "is both safe and feasible in patients with early breast cancer,...". However, we believe that these conclusions should be interpreted with caution because the present study has a few major limitations.